US2005124054A1PendingUtilityA1

Novel proteins and methods for producing the proteins

Priority: Feb 20, 1995Filed: Nov 3, 2004Published: Jun 9, 2005
Est. expiryFeb 20, 2015(expired)· nominal 20-yr term from priority
A61P 19/10C07K 14/70578
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Claims

exact text as granted — not AI-modified
1 - 31 . (canceled)  
     
     
         32 . A method of treating a bone disorder comprising administering a therapeutically effective amount of a purified and isolated polypeptide comprising OCIF.  
     
     
         33 . The method of  claim 32  wherein the polypeptide is human OCIF.  
     
     
         34 . The method of  claim 32  wherein the bone disorder is selected from the group consisting of osteoporosis and rheumatism.  
     
     
         35 . The method of  claim 32  wherein the bone disorder is accompanied by bone loss.  
     
     
         36 . A method of treating abnormal bone metabolism comprising administering an efficacious amount of OCIF protein.  
     
     
         37 . The method of  claim 36  wherein the OCIF protein is human OCIF protein.  
     
     
         38 . The method of  claim 36  wherein the abnormal bone metabolism is a decrease of bone mass.

Join the waitlist — get patent alerts

Track US2005124054A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.